Maria Vittoria Dieci

Author

Also Known As

Dieci, M.V., Dieci, Maria Vittoria, M V Dieci, M. Dieci, M. V. Dieci, M. Vittoria Dieci, M.V. Dieci, MARIA VITTORIA DIECI, Maria Dieci, Maria V Dieci

482

Publications

12.2K

Citations

H-Index

Concepts

All Affiliations

Istituto Oncologico Veneto University of Padua Istituti di Ricovero e Cura a Carattere Scientifico University of Modena and Reggio Emilia Inserm

About

Maria Vittoria Dieci is an author at Istituto Oncologico Veneto specializing in medicine, breast cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	29	2.4K
2	Health Sciences	4	4	272
3	Public Health	2	2	48
4	Engineering	1	1	17
5	Nursing	1	1	72

Maria Vittoria Dieci

Publications

6.6K

Citations

H-Index

Page 1

	Year	Citations
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers Sherene Loi, Damien Drubay, Sylvia Adams, Journal of Clinical Oncology	2019	828
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study Maria Vittoria Dieci, Carmen Criscitiello, Aïcha Goubar, Annals of Oncology Residual DiseaseBreast OncologyMedicinePrognostic ValueImmunology	2014	461
Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis Céline Lefèbvre, Thomas Bachelot, Thomas Filleron, PLoS Medicine	2016	388
Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials Maria Vittoria Dieci, Marie Mathieu, Valentina Guarneri, Annals of Oncology Tumor ImmunologyBreast OncologyCancer ImmunosurveillanceMedicinePhase Iii	2015	304
Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy J H Park, Sarah Flora Jonas, Guillaume Bataillon, Annals of Oncology Breast OncologyCancer ImmunosurveillanceMedicinePrognostic ValueImmunology	2019	259
Evolution of HER2-low expression from primary to recurrent breast cancer Federica Miglietta, Gaia Griguolo, Michele Bottosso, npj Breast Cancer	2021	211
Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy S.J. Luen, Roberto Salgado, Maria Vittoria Dieci, Annals of Oncology	2018	196
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer Zuzana Kos, Elvire Roblin, Rim S. Kim, npj Breast Cancer	2020	190
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-Institution analysis Maria Vittoria Dieci, Elena Barbieri, Federico Piacentini, Annals of Oncology Breast OncologyTumor HeterogeneityReceptor StatusMedicinePathology	2012	189
Rare Breast Cancer Subtypes: Histological, Molecular, and Clinical Peculiarities Maria Vittoria Dieci, Enrico Orvieto, Massimo Dominici, The Oncologist Tumor BiologyBreast OncologyTumor HeterogeneityMedicineBreast Cancer Classes	2014	172

Page 1